Tag: Kymriah

$FDA and EMA see Novartis’s Kymriah as an option for patients with relapsed or refractory B-cell ALL and DLBCL$

January 17, 2018 Off

FDA and EMA see Novartis’s Kymriah as an option for patients with relapsed or refractory B-cell ALL and DLBCL

The FDA has set Novartis’s Kymriah suspension injection for patients who have relapsed or refractory diffuse large B-cell lymphona (DLBCL)…

October 31, 2017 Off

By Dino Mustafić

Novartis said on Tuesday that it has submitted a supplemental Biologics License Application (sBLA) to the US Food and Drug…